体重波动与冠心病结局
该研究为对治疗至新目标试验的事后分析,纳入9509例冠心病患者,从基线和随访访视计算个体内体重波动。主要终点为任何冠脉事件。校正危险因素、基线血脂水平、平均体重和体重变化后,体重变异性每增加1个标准差(以平均连续变异性衡量,作为时间依赖协变量),任何冠脉事件风险增加(HR 1.04,95%CI 1.01-1.07,P=0.01),任何心血管事件风险增加(HR 1.04,95%CI 1.02-1.07,P<0.001),死亡风险增加(HR 1.09,95%CI 1.07-1.12,P<0.001)。体重波动最高五分位组与最低五分位组相比,冠脉事件风险高64%,心血管事件风险高85%,死亡风险高124%,心肌梗死风险高117%,卒中风险高136%。
要点
- 在冠心病患者中,校正危险因素、基线血脂水平、平均体重和体重变化后,体重变异性每增加1个标准差(以平均连续变异性衡量,作为时间依赖协变量),任何冠脉事件风险增加(HR 1.04,95%CI 1.01-1.07,P=0.01)。
- 体重变异性每增加1个标准差,任何心血管事件风险增加(HR 1.04,95%CI 1.02-1.07,P<0.001),死亡风险增加(HR 1.09,95%CI 1.07-1.12,P<0.001)。
- 体重波动最高五分位组与最低五分位组相比,校正模型下冠脉事件风险高64%,心血管事件风险高85%,死亡风险高124%,心肌梗死风险高117%,卒中风险高136%。
- 体重波动与冠心病患者死亡和心血管事件风险升高相关,且独立于传统心血管危险因素。
适用人群与场景
- 冠心病患者,来自治疗至新目标试验的9509例参与者。
研究设计与关键结果
- 研究类型:对治疗至新目标试验的事后分析;样本量9509例;人群为冠心病患者;干预与对照:评估阿托伐他汀降低低密度脂蛋白胆固醇水平的疗效和安全性;主要终点为任何冠脉事件(冠心病死亡、非致命性心肌梗死、复苏成功的心脏骤停、血运重建或心绞痛的复合终点)。
- 体重变异性以平均连续变异性衡量并作为时间依赖协变量;校正危险因素、基线血脂水平、平均体重和体重变化后,每增加1个标准差,任何冠脉事件风险增加(2091起事件;HR 1.04,95%CI 1.01-1.07,P=0.01),任何心血管事件风险增加(2727起事件;HR 1.04,95%CI 1.02-1.07,P<0.001),死亡风险增加(487起事件;HR 1.09,95%CI 1.07-1.12,P<0.001)。
- 体重波动最高五分位组与最低五分位组相比,校正模型下冠脉事件风险高64%,心血管事件风险高85%,死亡风险高124%,心肌梗死风险高117%,卒中风险高136%。
证据类型、等级与局限
- 证据类型:对治疗至新目标试验的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Body-weight fluctuation is a risk factor for death and coronary events in patients without cardiovascular disease. It is not known whether variability in body weight affects outcomes in patients with coronary artery disease.
METHODS: We determined intraindividual fluctuations in body weight from baseline weight and follow-up visits and performed a post hoc analysis of the Treating to New Targets trial, which involved assessment of the efficacy and safety of lowering low-density lipoprotein cholesterol levels with atorvastatin. The primary outcome was any coronary event (a composite of death from coronary heart disease, nonfatal myocardial infarction, resuscitated cardiac arrest, revascularization, or angina). Secondary outcomes were any cardiovascular event (a composite of any coronary event, a cerebrovascular event, peripheral vascular disease, or heart failure), death, myocardial infarction, or stroke.
RESULTS: Among 9509 participants, after adjustment for risk factors, baseline lipid levels, mean body weight, and weight change, each increase of 1 SD in body-weight variability (measured according to average successive variability and used as a time-dependent covariate) was associated with an increase in the risk of any coronary event (2091 events; hazard ratio, 1.04; 95% confidence interval [CI], 1.01 to 1.07; P=0.01), any cardiovascular event (2727 events; hazard ratio, 1.04; 95% CI, 1.02 to 1.07; P<0.001), and death (487 events; hazard ratio,1.09; 95% CI, 1.07 to 1.12; P<0.001). Among patients in the quintile with the highest variation in body weight, the risk of a coronary event was 64% higher, the risk of a cardiovascular event 85% higher, death 124% higher, myocardial infarction 117% higher, and stroke 136% higher than it was among those in the quintile with the lowest variation in body weight in adjusted models.
CONCLUSIONS: Among participants with coronary artery disease, fluctuation in body weight was associated with higher mortality and a higher rate of cardiovascular events independent of traditional cardiovascular risk factors. (Funded by Pfizer; ClinicalTrials.gov number, NCT00327691 .).
参考来源
- Bangalore S, Fayyad R, Laskey R, et al. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med. 2017. PMID: 28379800. doi:10.1056/NEJMoa1606148
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。